B · Normal
On September 21, the CEO of Novo Nordisk stated that it would launch new innovative drugs for diabetes and obesity before losing its exclusive patent rights.
Related telegraphs
[Novo Nordisk responds to "Simeglutide reflux drugs": supports and fully coopera
09-22 11:06
[The concept of innovative drugs rebounded in shock, and Hokuriku Pharmaceutical
09-22 09:52
On September 21, Novo Nordisk stated that Mexico is the next market for Wegovy o
09-21 20:59
On September 21, the head of Novo Nordisk in the United States said that since J
09-21 20:19
On September 21, Novo Nordisk’s Chief Scientific Officer (CSO) stated that at le
09-21 16:49
On September 21, Novo Nordisk’s CEO stated that by 2030, the company’s productio
09-21 16:28
Comments